Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Thoracoscopic Pleural Biopsy in Sohag University Hospital

NCT06964308 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2025-05-09

Condition(s) studied

Pleural Diseases

Investigational drug(s) / intervention(s)

thoracoscopic pleural biopsy.

thoracoscopic pleural biopsy.: This intervention aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.

Study summary

This study aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with suspected pleural disease who have been referred for thoracoscopic pleural biopsy * Age: Adults aged 18 years and older * Patients should have undergone necessary preoperative evaluations, including imaging studies (e.g., chest X-ray, CT scan) that indicate a need for biopsy. Exclusion Criteria: * Contraindications to Thoracoscopic Biopsy: Patients with contraindications to thoracoscopic biopsy * Infeasibility of Procedure: Patients with anatomical or physiological factors that make thoracoscopic biopsy technically unfeasible or unsafe (e.g., severe pleural adhesions or distorted anatomy). * Alternative Diagnoses: Patients who have been definitively diagnosed with a condition that does not require thoracoscopic biopsy for further evaluation. * Pregnancy: Pregnant women may be excluded due to potential risks to the fetus and the need for specific procedural considerations. * Inability to Provide Consent: Patients who are unable to provide informed consent due to cognitive impairment, language barriers, or other reasons. * Participation in Concurrent Studies: Patients currently participating in other clinical studies that could interfere with the outcomes of this study or affect their eligibility.

Primary outcome measure(s)

  • early postoperative follow up for thoracoscopic pleural biopsy in the management of pleural diseases. — 3 days after procedure
    return to daily activity

Trial sites (1)

FacilityCityRegionStatus
Sohag University Hospital Sohag Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06964308 on ClinicalTrials.gov ↗ ← All trials in Egypt